Clinical response and safety of apatinib monotherapy in recurrent, metastatic cervical cancer after failure of chemotherapy: a retrospective study.
CONCLUSIONS: Apatinib can improve the disease control rate of recurrent and metastatic cervical cancer when chemotherapy has failed, and the treatment is well tolerated. This represents that apatinib may be a new treatment option for metastatic cervical cancer patients.
PMID: 31788992 [PubMed - as supplied by publisher]
Source: Journal of Gynecologic Oncology - Category: OBGYN Tags: J Gynecol Oncol Source Type: research
More News: Adenocarcinoma | Cancer | Cancer & Oncology | Carcinoma | Cervical Cancer | Chemotherapy | Hypertension | OBGYN | Oral Cancer | Proteinuria | Skin Cancer | Squamous Cell Carcinoma | Study